Navin Fluorine International Ltd-$ — Q4 FY26 earnings call
Summary generated by AI from the official transcript Navin Fluorine International Ltd-$ filed with BSE on 04 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Navin Fluorine reported consolidated Q4 FY26 revenue of Rs 938 crore, up 34% year-on-year, with operating EBITDA up 80% to Rs 321 crore and profit after tax up 124% to Rs 213 crore. For the full year, net operating revenue grew 41% to Rs 3,314 crore, operating EBITDA more than doubled to Rs 1,082 crore, and profit after tax rose to Rs 664 crore from Rs 289 crore. Management discussed segment performance across HPP, Specialty Chemicals and CDMO, capex projects including the Chemours plant and R32 capacity expansion, and addressed questions on raw material availability, pricing, and demand trends amid geopolitical uncertainty.
Numbers mentioned
Consolidated Revenue: Rs 938 crores (Q4 FY26)
p. 5
“Consolidated revenue stood at INR938 crores, registering a 34% year-on-year growth.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Operating EBITDA: Rs 321 crores (Q4 FY26)
p. 5
“Operating EBITDA increased 80% year-on-year to INR321 crores with margins expanding to 34.2%.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Operating PBT: Rs 251 crores (Q4 FY26)
p. 5
“Operating PBT grew 118% year-on-year to INR251 crores.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Profit after tax: Rs 213 crores (Q4 FY26)
p. 5
“Profit after tax stood at INR213 crores, reflecting a growth of 124%.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Net operating revenue: Rs 3,314 crores (FY26)
p. 5
“For the full year FY26, net operating revenues grew to INR3,314 crores, reflecting a growth of 41%, supported by broad-based momentum across specialty chemicals, CDMO and HPP.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Operating EBITDA: Rs 1,082 crores, margin 32.6% (FY26)
p. 5
“Operating EBITDA more than doubled to INR1,082 crores with margins at 32.6%, an expansion of 992 basis points, reflecting a favorable mix and operating leverage.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Operating PBT: Rs 815 crores (FY26)
p. 5
“Operating PBT grew 142% year-on-year to INR815 crores as against INR336 crores in the last – FY ‘25.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Profit after tax: Rs 664 crores (FY26)
p. 5
“Profit after tax stood at INR664 crores as against INR289 crores.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Net working capital days: 74 days versus 90 days (FY26)
p. 5
“Our net working capital days have improved to 74 days versus 90 days, reflecting a stronger operational efficiency and better conversion cycle.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Net debt to equity: 0.01x (as of 31 March 2026)
p. 5
“As of 31 March 2026, our net debt to equity stood at 0.01x negligible, while both ROE and ROCE improved at 20% and 21%, respectively.”
Anish Ganatra, page 5 of the filed PDF · View the filing
HPP segment revenue: Rs 393 crores, up 20% YoY (Q4 FY26)
p. 4
“Quarter 4 FY26 revenue grew 20% year-on-year at INR393 crores, driven by improved realization and volume growth.”
Nitin Kulkarni, page 4 of the filed PDF · View the filing
Specialty Chemicals revenue: Rs 360 crores, up 39% YoY (Q4 FY26)
p. 4
“Q4 FY26 revenue grew 39% year-on-year at INR360 crores, reflecting strong execution in both existing and new molecules.”
Nitin Kulkarni, page 4 of the filed PDF · View the filing
CDMO revenue: Rs 186 crores, up 61% YoY (Q4 FY26)
p. 4
“Quarter 4 FY26 revenue grew by 61% year-on-year to INR186 crores.”
Nitin Kulkarni, page 4 of the filed PDF · View the filing
CDMO full-year revenue: Rs 541 crores (FY26)
p. 8
“this number that we've delivered this year of INR541 crores is again a solid sort of journey to kind of get to where we want to get to by FY27.”
Anish Ganatra, page 8 of the filed PDF · View the filing
Final dividend: Rs 8.6 per equity share, 430% of face value (FY26)
p. 3
“the Board in today's meeting has declared a final dividend of INR8.6 per equity share, 430% of the face value of INR2 per share.”
Vishad Mafatlal, page 3 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Net working capital days — 75 to 80 days
stated firmly by Anish Ganatra
p. 5
“Going forward, the net working capital is expected to be in the range of 75 to 80 days versus our previous indicative guidance of 90 days of sales.”
Anish Ganatra, page 5 of the filed PDF · View the filing
R32 capacity commissioning — 15,000 metric tons per annum · Q3 FY27
stated firmly by Nitin Kulkarni
p. 4
“Our additional HFC capacity expansion equivalent to 15,000 metric tons per annum of R32 remains on track for commissioning in quarter 3 FY27.”
Nitin Kulkarni, page 4 of the filed PDF · View the filing
Dahej MPP debottlenecking capex commissioning — Q3 FY27
stated firmly by Nitin Kulkarni
p. 4
“Our Dahej MPP debottlenecking capex is progressing well and is targeted for commissioning in quarter 3 FY27.”
Nitin Kulkarni, page 4 of the filed PDF · View the filing
Chemours project completion — end June, early July
stated firmly by Nitin Kulkarni
p. 4
“The Chemours project is on track and expected to be completed by end June, early July.”
Nitin Kulkarni, page 4 of the filed PDF · View the filing
EBITDA margin — 30%, plus/minus 1% to 2% · FY27
stated conditionally by Anish Ganatra
p. 17
“we've always maintained that we will endeavor to do 30%. Given what we know today of the business circumstances, plus/minus 1% to 2%, which we've always said, yes.”
Anish Ganatra, page 17 of the filed PDF · View the filing
CDMO revenue target — $100 million · FY27
stated as an aspiration by Anish Ganatra
p. 8
“as we look into coming into our FY27 number that we've always said of $100 million”
Anish Ganatra, page 8 of the filed PDF · View the filing
Agrochemical capacity utilization — about 80% · FY27
stated firmly by Anish Ganatra
p. 8
“as we look into FY27, we have visibility almost up to about 80% of our capacity utilization.”
Anish Ganatra, page 8 of the filed PDF · View the filing
Nectar plant utilization — 75% to 80% · end of FY28
stated as an aspiration by Anish Ganatra
p. 16
“we would have liked to have a full utilization by end of FY28, which would be the 2 years. But I think we are realistically talking about 75% to 80% is where we will get to by end of FY28.”
Anish Ganatra, page 16 of the filed PDF · View the filing
Employee benefit expenses — 7.5% to 9%
stated firmly by Anish Ganatra
p. 11
“if you had to put your model in, I would model it in the range of between 7.5%, 8.5%, 9%, not more than that.”
Anish Ganatra, page 11 of the filed PDF · View the filing
HFO capacity utilization at Honeywell contract — additional 20%
stated as an aspiration by Anish Ganatra
p. 16
“there is room to expand within that same capacity by another 20%.”
Anish Ganatra, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the situation remains volatile but no material risk or disruption has been seen so far, with price increases being passed on to customers.
Answered by Anish Ganatra
Asked by Sanjesh Jain: Is there a raw material availability challenge in the Middle East and how will inflation be passed through on contracts?
p. 6
“So far, we have not seen any disruption. We have seen inflation go through.”
Anish Ganatra, page 6 of the filed PDF · View the filing
Management said the notification doesn't change quota-based dynamics, and the company's right to win comes from having the necessary quota.
Answered by Anish Ganatra
Asked by Sanjesh Jain: Does the new refrigerant gas notification allowing capacity addition until 2027 change the R32 pricing scenario?
p. 7
“So your right to win comes from the quota that you have. And that's exactly what we've always been saying and which is why we put our capacity to consume our quota fully.”
Anish Ganatra, page 7 of the filed PDF · View the filing
Management said the currency tailwind is largely offset by inflation, and most of the EBITDA margin expansion came from capacity and volume growth rather than pricing.
Answered by Anish Ganatra
Asked by Sanjesh Jain: What is the margin benefit purely from currency versus inflation?
p. 7
“I think it's about 990 basis points from FY to FY, you will see 70% of that for Navin is coming from our capacities coming on the ground, our volumes going up and 30% is coming from affirmative actions on pricing that we've taken.”
Anish Ganatra, page 7 of the filed PDF · View the filing
Management said the company is working on about 50-55 molecules split roughly evenly between late-stage/commercial and early-stage.
Answered by Anish Ganatra
Asked by Sanjesh Jain: How many late-stage CDMO contracts are in the pipeline?
p. 8
“I think we are working close to about 50, 55 molecules, half of them being in late-stage commercial and half of them being in early stages.”
Anish Ganatra, page 8 of the filed PDF · View the filing
Management said it is premature to specify capex, with clarity expected as the market size becomes better understood over the next 18 months.
Answered by Anish Ganatra
Asked by Naushad Choudhary: What capex could the Chemours project trigger and when will there be visibility?
p. 8
“As we move to that over the next sort of 18 months, we get a better understanding of what that market size looks like. And accordingly, there will be a capex that will be rolled on the back of that understanding.”
Anish Ganatra, page 8 of the filed PDF · View the filing
Management said service contracts typically have pass-through mechanisms and price rises are not a surprise to customers.
Answered by Anish Ganatra
Asked by Rohit Nagraj: Will raw material price inflation be passed on immediately or with a lag under service contracts?
p. 9
“In service play, typically, you have pass-through mechanisms. So this will fall into that pass-through mechanism.”
Anish Ganatra, page 9 of the filed PDF · View the filing
Management said cost optimization is complete and expects normal increments going forward within a defined range.
Answered by Anish Ganatra
Asked by Rohit Nagraj: Will employee benefit expenses normalize in FY27 given the scale-up in operations?
p. 10
“I think we are done with the optimization where we are. So going forward, you will see the increase largely.”
Anish Ganatra, page 10 of the filed PDF · View the filing
Management said the agrochemical business is export-driven with solid order visibility and no demand disruption seen.
Answered by Anish Ganatra
Asked by Vivek Rajamani: Are customers moving toward sustainable restocking, and is there risk to agrochemical offtake from fertilizer dislocations?
p. 11
“We are not seeing any disruption on that front.”
Anish Ganatra, page 11 of the filed PDF · View the filing
Management outlined multiple growth drivers including HF plant, Nectar ramp-up, R32 capacity and Chemours, expressing confidence in double-digit growth.
Answered by Anish Ganatra
Asked by Jason Soans: Can Specialty Chemicals and HPP segments sustain high double-digit revenue growth in FY27 from a higher base?
p. 13
“I would be surprised if it's not double-digit, but I'm happy to clarify if it is not separately.”
Anish Ganatra, page 13 of the filed PDF · View the filing
Management said Middle East export exposure is minimal and shipments have not gone out yet, with any resumption being an upside.
Answered by Anish Ganatra
Asked by Jason Soans: Did the Middle East crisis impact refrigerant gas volumes?
p. 13
“So if any of that comes in, it will be an upside. But the demand across the globe is pretty robust and also no logistics issues on that front.”
Anish Ganatra, page 13 of the filed PDF · View the filing
Management attributed the decline to planned shutdowns and catalyst recharge activity, plus the absence of Middle East shipments.
Answered by Anish Ganatra
Asked by Arun Prasath: Why did HPP segment revenue decline sequentially despite AHF plant scale-up?
p. 15
“we had taken a planned shutdown in our Q4, and we also took an opportunistic exercise to recharge the catalyst in one of our plants.”
Anish Ganatra, page 15 of the filed PDF · View the filing
Management pointed to the already-commissioned HF plant and room to expand Honeywell-related capacity utilization by 20%.
Answered by Anish Ganatra
Asked by Keyur Pandya: What growth levers exist in HPP ahead of the new R32 plant, including the Honeywell contract?
p. 16
“whatever we are doing on demand today, it is at an 80% capacity, as I've told you before. So there is room to expand within that same capacity by another 20%.”
Anish Ganatra, page 16 of the filed PDF · View the filing
Management said margin outcomes depend on the specific product mix within and across business verticals each quarter.
Answered by Anish Ganatra
Asked by Abhijit Akella: Why haven't gross margins expanded more given CDMO ramp-up?
p. 17
“there were 13 molecules we did in FY26 in the specialty business, three of them were done in quarter 4.”
Anish Ganatra, page 17 of the filed PDF · View the filing
Management said qualification campaigns with 2-3 other customers are underway, with the plan now expected to reach 75% this year and the balance the following year.
Answered by Anish Ganatra
Asked by Archit Joshi: How will the remaining 50% of Nectar plant capacity be placed given global agri industry conditions?
p. 18
“we are talking of the 75% this year and then the balance next year.”
Anish Ganatra, page 18 of the filed PDF · View the filing
Management confirmed the dedicated block will take over existing production and said there is visibility for additional volumes, potentially triggering a cGMP5 phase.
Answered by Anish Ganatra
Asked by Dhara Ganatra: Will Fermion manufacturing move fully to the new cGMP4 block and is there visibility for more volumes?
p. 18
“Yes, there will be a Phase 2. And obviously, we are working with other molecules, too. So we've got space for 5, 6 and 7, I believe.”
Anish Ganatra, page 18 of the filed PDF · View the filing
Risks flagged
Volatile Middle East raw material and geopolitical situation
p. 6
“the situation continues to remain volatile.”
Anish Ganatra, page 6 of the filed PDF · View the filing
Potential global demand slowdown from sustained high oil prices
p. 14
“at $150 sustained oil prices, I think there is a concern that the global demand may slow.”
Anish Ganatra, page 14 of the filed PDF · View the filing
Geopolitical developments affecting energy prices, logistics and supply chains
p. 5
“We are closely monitoring and navigating the developments with agility, particularly given implications on energy prices, logistics and supply chain disruptions.”
Nitin Kulkarni, page 5 of the filed PDF · View the filing
Agrochemical pricing remains subdued amid a slow market reset
p. 8
“Pricing is always going to be lagging that.”
Anish Ganatra, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.